Pure Global

TorasEmide Induced Effect on Quality of Life and Clinical parameterS in paTients With chronIc heArt Failure Receiving Eplerenone. - Trial NCT06117722

Access comprehensive clinical trial information for NCT06117722 through Pure Global AI's free database. This phase not specified trial is sponsored by Elpen Pharmaceutical Co. Inc. and is currently Not yet recruiting. The study focuses on Chronic Heart Failure. Target enrollment is 210 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06117722
Not yet recruiting
other
Trial Details
ClinicalTrials.gov โ€ข NCT06117722
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
TorasEmide Induced Effect on Quality of Life and Clinical parameterS in paTients With chronIc heArt Failure Receiving Eplerenone.
ESTIA: TorasEmide Induced Effect on Quality of Life and Clinical parameterS in paTients With chronIc heArt Failure Receiving Eplerenone. Multicenter, Non-interventional, Prospective, Observational Clinical Study.

Study Focus

Chronic Heart Failure

Eplerenone torasemide in chronic heart failure

Observational

other

Sponsor & Location

Elpen Pharmaceutical Co. Inc.

Timeline & Enrollment

N/A

Jan 01, 2024

Dec 31, 2024

210 participants

Primary Outcome

Minnesota Living with Heart Failure (MLHF)

Summary

Heart failure (HF) is a multisystemic disorder characterized by marked disturbances in the
 physiology of the circulatory system and a multitude of structural and functional changes in
 the myocardium that adversely affect the systolic function and diastolic filling of the
 heart. Heart failure is not a single pathologic diagnosis, but a clinical syndrome consisting
 of cardiac symptoms (eg, dyspnea, edema of the lower extremities, and fatigue) that may be
 accompanied by signs (eg, increased jugular venous pressure and peripheral edema).The
 diagnosis of CKD becomes more likely in patients with a history of myocardial infarction
 (MI), arterial hypertension, coronary artery disease (CHD), diabetes mellitus, alcohol abuse,
 chronic kidney disease (CKD), cardiotoxic chemotherapy, and in patients with a family history
 of cardiomyopathy or of sudden death. The diagnosis of HF requires the presence of HF
 symptoms and/or signs and objective evidence of cardiac dysfunction.
 
 The main symptoms of HF are symptoms such as shortness of breath at rest or during exercise,
 difficulty breathing (dyspnea), rapid breathing (tachypnea), difficulty breathing when
 bending over (bendopnea), orthopnea, paroxysmal nocturnal dyspnea, fatigue , weight gain or
 weight loss, swelling (of the extremities, scrotum or elsewhere), wheezing, palpitations,
 syncope, history of Cheyne Stokes breathing during sleep (often reported by the family rather
 than the patient), cough, drowsiness.
 
 The simplest terminology used to describe HF severity is the New York Heart Association
 (NYHA) functional classification based on symptom severity and physical activity.
 
 In Greece, it is estimated that the number of patients suffering from HF is 200,000.
 
 In the vast majority of cases, transthoracic echocardiography is the initial cardiac imaging
 test used to evaluate patients with newly diagnosed or suspected heart failure.
 Echocardiography is particularly suitable for the evaluation of myocardial structure and
 function, valvular function and hemodynamic parameters .

ICD-10 Classifications

Heart failure
Heart failure, unspecified
Congestive heart failure
Hypertensive heart disease with (congestive) heart failure
Hypertensive heart disease without (congestive) heart failure

Data Source

ClinicalTrials.gov

NCT06117722

Non-Device Trial